Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products.
Our strategy is rooted in four strategic imperatives that have remained constant since we began in 2011 to transform Pfizer.
Improve Pfizer's ability to innovate in biomedical R&D and develop a new generation of high value, highly differentiated medicines and vaccines.
Invest and allocate our resources in ways that create the greatest long-term returns for our shareholders.
Earn society's respect by generating breakthrough therapies, improving access, expanding the dialogue on health care and acting as a responsible corporate citizen.
Build and sustain a culture where colleagues view themselves as owners, generating new ideas, dealing with problems in a straightforward way, investing in open and candid conversations and working as teammates on challenges and opportunities.
assets in our current product pipeline (as of January 31, 2017)
employees (as of December 31, 2016)
to shareholders through dividends and share repurchases in 2016
per share in dividends in 2017
Strong revenue growth in 2016 and a differentiated and diverse group of products
Building a strong capacity in immuno-oncology through partnerships with Merck KGaA and IBM
2 regulatory milestones received from the EMA and the FDA for vaccines to prevent meningococcal disease
A strong portfolio and a presence in over 125 countries
80 assets in our global portfolio, the largest in the industry
3 marketed products and 14 biosimilars in the pipeline
doses of Prevenar 13® delivered to Gavi, the Vaccine Alliance, protecting infants in 45 low-income nations
doses of the antibiotic Zithromax® donated to support the International Trachoma Initiative and fight the world’s leading cause of preventable blindness
patients in the U.S. obtained their medicines for free or at substantial discount through Pfizer RxPathways®
Held fourth annual global OWNIT! Day in April 2016 as colleagues took time to reflect and celebrate Pfizer's OWNIT! culture, with a core focus on accountability.
Are open to all colleagues and help drive diversity and inclusion (D&I) throughout our business.
Is an international corporate volunteer program where Pfizer colleagues use their health and business expertise to promote access, quality, outcomes and efficiency of health services for people in need.
The webcast may include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from our business development transactions and plans relating to share repurchases and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.